证券代码：000950 证券简称：重药控股 公告编号：2025-068 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，重药控 股股份有限公司（以下简称"公司"）将参加在重庆证监局指导下，由重庆上市公 司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司 2025 年投资者 网上集体接待日活动"（以下简称"本次活动"），现将有关事项公告如下： 1.本次活动的时间：2025 年 9 月 25 日（星期四）15:00-17:00。 重药控股股份有限公司 关于参加重庆辖区上市公司 2025 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2.本次活动的交流网址：本次活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式进行，投资者可以登录网址：http://ir.p5w.net 进入 专区页面参与交流。 3.届时公司相关高管人员将通过网络在线交流形式，就投资者所关心的问题， 与投资者进行"一对多"形式的互动交流。欢迎广大投资者积极参与本次活动。 特此公告 重药控股股份有限公司董事会 2025 年 9 月 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-067 重药控股股份有限公司 关于控股股东股权结构拟发生变更的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 6 月 19 日，重药控股股份有限公司（以下简称"公司"）披露了《关 于控股股东股权结构拟发生变更的提示性公告》（公告编号：2025-039），公司 控股股东重药医药健康产业有限公司（以下简称"重庆医健"）的股东重庆渝富控 股集团有限公司（以下简称"重庆渝富"）在重庆联合产权交易所集团股份有限公 司（以下简称"重庆联交所"）公开挂牌转让重庆医健 24%股权（以下简称"本次 交易"）。 2025 年 8 月 22 日，公司披露了《关于控股股东股权结构拟发生变更的进展 公告》（公告编号：2025-063），重庆联交所确定本次交易的最终受让方为中国 通用技术（集团）控股有限责任公司（以下简称"通用技术集团"）。交易双方 经协商将按照重庆联交所的相关流程以交易底价 22.06 亿元签订产权交易合同。 2025 年 8 月 27 日，公司披露了《关于控股股东股权结构拟发生变更 ...

Core Viewpoint - The company Chongqing Pharmaceutical Holdings (重药控股) has received the clinical trial approval notice for its drug, Prasugrel Hydrochloride Tablets, from the National Medical Products Administration (NMPA) of China, indicating progress in its drug development process [1] Group 1 - The company announced on September 12 that it will soon commence clinical trials for Prasugrel Hydrochloride Tablets following the receipt of the approval notice [1] - According to Chinese drug registration laws and regulations, the drug must undergo clinical trials and receive further review and approval from the NMPA before it can be manufactured and marketed [1] - The drug development process is lengthy and involves multiple stages, making it susceptible to various uncertainties [1]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2% of the company's total shares, amounting to approximately 174 million shares [1] - Jinlongyu's shareholder terminates the share transfer agreement, halting the planned transfer of 5.32% of the company's shares [1] - Doli Technology's subsidiary plans to establish a joint venture in Spain with an investment of approximately 505 million yuan, with a 70% stake held by Doli Technology [1][2] Group 2 - Chongqing Pharmaceutical, a subsidiary of Zhongyao Holdings, has received approval for clinical trials of its drug, Clopidogrel Hydrochloride Tablets [3][4] - Dongyangguang plans to jointly increase capital in a subsidiary to acquire 100% of Qinhuai Data China for 28 billion yuan [5] - Kangzhi Pharmaceutical's controlling shareholder intends to transfer 5.0004% of the company's shares at a price of 5.34 yuan per share, totaling approximately 122 million yuan [6] Group 3 - Huali Co., Ltd. announces two shareholders plan to reduce their stakes by a combined total of up to 3.96% of the company's shares [7] - Fangbang Co., Ltd.'s director plans to reduce his stake by up to 15,000 shares, representing 0.1844% of the total shares [8] - China Pacific Insurance suggests issuing HKD-denominated convertible bonds, with proceeds aimed at supporting its main insurance business and strategic initiatives [9] Group 4 - Microchip Biotech's shareholder plans to reduce its stake by up to 3% of the company's total shares [10] - Hongbai New Materials' controlling shareholder intends to reduce its stake by up to 3% due to funding needs [11] - Zhejiang Rongtai clarifies that its sales in the robotics components sector are minimal and will not significantly impact annual net profit [12] Group 5 - ST Tianmao voluntarily withdraws its application for A-share listing, which has been accepted by the Shenzhen Stock Exchange [13] - Qingxin Environment's shareholder plans to reduce its stake by up to 1% of the company's total shares [14] - Lanjik Technology's two shareholders plan to reduce their stakes by a combined total of up to 2% of the company's shares [15] Group 6 - BYD's executives and core personnel collectively increased their holdings in the company by approximately 52.33 million yuan [16] - Trina Solar's subsidiary signs contracts for the sale of 2.48 GWh of energy storage products, marking a significant overseas order [17] - Chutianlong's shareholder plans to reduce its stake by up to 3% of the company's total shares [18] Group 7 - Zhongjuxin's shareholder plans to reduce its stake by up to 2.5% of the company's total shares due to funding needs [19] - ST Hezhong's controlling shareholder is under bail pending trial, but company operations remain unaffected [20] - Shoukai Co., Ltd. reports a signed contract amount of 973 million yuan for August, with cumulative contracts of 13.15 billion yuan for the year [21] Group 8 - Jucheng Co., Ltd.'s shareholder plans to reduce its stake by up to 2.61% of the company's total shares due to personal funding needs [22]

Company Overview - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug named Prasugrel Hydrochloride Tablets [1] - Zhongyao Holdings reported a market capitalization of 9 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Zhongyao Holdings is as follows: 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration to conduct clinical trials for its drug, which is currently not available in China [1] Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, is set to initiate clinical trials for the drug, which is a third-generation platelet aggregation inhibitor [1] - The drug, Prasugrel Hydrochloride Tablets, is indicated for preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1] Industry Summary - The drug is already marketed in over 70 countries and regions globally, indicating its established presence in the international pharmaceutical market [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration for clinical trials of Prasugrel Hydrochloride Tablets, marking a significant step in expanding its product portfolio in the cardiovascular drug market [1]. Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, has been granted a clinical trial approval for Prasugrel Hydrochloride Tablets by the National Medical Products Administration [1]. - Prasugrel Hydrochloride is a third-generation drug that inhibits ADP-induced platelet aggregation, aimed at preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]. - The original developer of Prasugrel is Daiichi Sankyo Co., Ltd., and the drug is currently available in over 70 countries and regions worldwide, although it has not yet been launched in China [1].

关于子公司药物获临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，重药控股股份有限公司（以下简称"公司"）控股子公司重庆医药（集 团）股份有限公司（以下简称"重药股份"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的《药物临床试验批准通知书》，将于近期开展临床试验。 现将有关情况公告如下： 证券代码：000950 证券简称：重药控股 公告编号：2025-066 重药控股股份有限公司 二、其他相关情况 盐酸普拉格雷片原研公司为第一三共株式会社，是第三代的抑制 ADP 激活 的血小板聚集的药物，适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉 综合征、稳定型心绞痛、陈旧性心肌梗塞患者的血栓形成。目前已在全球 70 多 个国家和地区上市（中国境内未上市）。 重药股份投资引进第一三共株式会社的盐酸普拉格雷片技术及独家专利授权， 于 2021 年 8 月提交上市注册申请并获受理。因需进一步完善申报资料，经审慎研 究决定，于 2023 年 7 月主动撤回申请。2025 年 6 月，重药股份临床试验申请获得 受理，具体信息详见公司在巨潮资 ...

Core Viewpoint - Zhongyao Holdings (000950) announced that its subsidiary, Zhongyao Co., has received the clinical trial approval notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which will soon commence clinical trials [1] Company Summary - The drug is indicated for the prevention of thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]